All In Biotech

Drug Trial Radar · NCT04469621

A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Jul 17, 2020

Primary completion

Oct 23, 2020

Study completion Oct 23, 2020

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To evaluate the effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by C-reactive protein (CRP) levels in adult patients hospitalized with severe coronavirus disease 2019 (COVID-19) Secondary Objectives: * To evaluate the time to onset of effect of SAR443122 relative to the control arm on the hyperinflammatory state as measured by CRP levels * To evaluate the time to onset of effect of SAR443122 relative to the control arm on oxygenation status * To evaluate the effect of SAR443122 relative to the control arm on oxygenation status * To evaluate the effect of SAR443122 relative to the control arm on total duration of supplemental oxygen requirement * To evaluate the effect of SAR443122 relative to the control arm on length of ventilator support needed * To evaluate the effect of SAR443122 relative to the control arm on laboratory markers of severe COVID-19 * To evaluate the effect of SAR443122 relative to the control arm on mortality * To evaluate the effect of SAR443122 relative to the control arm on need for thrombolytic therapy * To evaluate the effect of SAR443122 relative to the control arm on need for vasopressor treatment * To evaluate the safety of SAR443122 as compared to the control arm up to End of Study * To evaluate the effect of SAR443122 relative to the control arm on total duration without high flow supplemental oxygen requirements

Conditions

  • Corona Virus Infection

Interventions

  • SAR443122Drug

    Pharmaceutical form:capsule Route of administration: oral

  • PlaceboDrug

    Pharmaceutical form:capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change from baseline in CRP levelTime frame: Day 7

Locations

10 sites in 5 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 0320001

    Caba, Argentina

  • Investigational Site Number 0760003

    Porto Alegre, Brazil

  • Investigational Site Number 0760001

    São José do Rio Preto, Brazil

  • Investigational Site Number 0760002

    São Paulo, Brazil

  • Investigational Site Number 1520001

    Santiago, Chile

  • Investigational Site Number 1520003

    Santiago, Chile

  • Investigational Site Number 1520002

    Talca, Chile

  • Investigational Site Number 4840001

    Monterrey, Mexico

  • Investigational Site Number 6430001

    Moscow, Russia

  • Investigational Site Number 6430002

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.